AT2221
ATB200-07
Phase 3 small_molecule completed
Quick answer
AT2221 for Pompe Disease (Late-onset) is a Phase 3 program (small_molecule) at AMICUS THERAPEUTICS PTY LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AMICUS THERAPEUTICS PTY LTD
- Indication
- Pompe Disease (Late-onset)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed